Trial Profile
Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With Opioid Induced Constipation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 May 2022
Price :
$35
*
At a glance
- Drugs Naloxegol (Primary)
- Indications Constipation
- Focus Adverse reactions; Therapeutic Use
- Acronyms NACASY
- Sponsors Kyowa Kirin Pharmaceutical Development
- 13 May 2022 Status changed from active, no longer recruiting to completed.
- 21 Sep 2020 Interim Results evaluating quality of life and safety of naloxegol for patients with cancer pain diagnosed with opioid induced constipation, presented at the 45th European Society for Medical Oncology Congress
- 09 Sep 2020 Planned End Date changed from 6 Sep 2020 to 30 Nov 2020.